Which has preferable earnings & valuation, XGN or SBC?

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 1.58 -$19.95M -$0.75 N/A SBC Medical Group $173.61M 4.35 $50.99M $0.47 15.64

Is XGN or SBC more profitable?

SBC Medical Group has a net margin of 27.99% compared to Exagen's net margin of -25.14%. SBC Medical Group's return on equity of 18.47% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -25.14% -125.60% -33.46% SBC Medical Group 27.99% 18.47% 13.10%

Does the media prefer XGN or SBC?

In the previous week, Exagen had 20 more articles in the media than SBC Medical Group. MarketBeat recorded 38 mentions for Exagen and 18 mentions for SBC Medical Group. SBC Medical Group's average media sentiment score of 0.46 beat Exagen's score of 0.30 indicating that SBC Medical Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 10 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral SBC Medical Group 4 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SRTA or XGN?

In the previous week, Exagen had 33 more articles in the media than Strata Critical Medical. MarketBeat recorded 38 mentions for Exagen and 5 mentions for Strata Critical Medical. Strata Critical Medical's average media sentiment score of 0.55 beat Exagen's score of 0.30 indicating that Strata Critical Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Strata Critical Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Exagen 10 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has better valuation & earnings, XGN or VMD?

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 1.58 -$19.95M -$0.75 N/A Viemed Healthcare $270.28M 1.29 $14.93M $0.38 24.13

Is XGN or VMD more profitable?

Viemed Healthcare has a net margin of 5.03% compared to Exagen's net margin of -25.14%. Viemed Healthcare's return on equity of 10.64% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -25.14% -125.60% -33.46% Viemed Healthcare 5.03% 10.64% 7.73%

Does the media prefer XGN or VMD?

In the previous week, Exagen had 31 more articles in the media than Viemed Healthcare. MarketBeat recorded 38 mentions for Exagen and 7 mentions for Viemed Healthcare. Viemed Healthcare's average media sentiment score of 0.39 beat Exagen's score of 0.30 indicating that Viemed Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 10 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Viemed Healthcare 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer XGN or TACO?

Exagen presently has a consensus price target of $9.88, suggesting a potential upside of 139.10%. Given Exagen's stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than Berto Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Berto Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, XGN or TACO?

Berto Acquisition has lower revenue, but higher earnings than Exagen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 1.58 -$19.95M -$0.75 N/A Berto Acquisition N/A N/A N/A N/A N/A

Does the media prefer XGN or TACO?

In the previous week, Exagen had 33 more articles in the media than Berto Acquisition. MarketBeat recorded 38 mentions for Exagen and 5 mentions for Berto Acquisition. Berto Acquisition's average media sentiment score of 1.33 beat Exagen's score of 0.30 indicating that Berto Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 10 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Berto Acquisition 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, INFU or XGN?

InfuSystem has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $144.44M 2.06 $870K $0.45 32.71 Exagen $66.57M 1.58 -$19.95M -$0.75 N/A

Is INFU or XGN more profitable?

InfuSystem has a net margin of 1.12% compared to Exagen's net margin of -25.14%. InfuSystem's return on equity of 2.78% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets InfuSystem 1.12% 2.78% 1.41% Exagen -25.14% -125.60% -33.46%

Does the media refer more to INFU or XGN?

In the previous week, Exagen had 34 more articles in the media than InfuSystem. MarketBeat recorded 38 mentions for Exagen and 4 mentions for InfuSystem. Exagen's average media sentiment score of 0.30 beat InfuSystem's score of 0.24 indicating that Exagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InfuSystem 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exagen 10 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral

Exagen (XGN) Competitors

$4.13 -0.28 (-6.35%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$4.07 -0.06 (-1.45%)

As of 11/13/2026 07:41 PM Eastern

Compare

XGN vs. SBC, SRTA, VMD, TACO, and INFU

Should you buy Exagen stock or one of its competitors? Exagen's main competitors and comparable companies include SBC Medical Group (SBC), Strata Critical Medical (SRTA), Viemed Healthcare (VMD), Berto Acquisition (TACO), and InfuSystem (INFU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Exagen compare to SBC Medical Group?

Exagen (NASDAQ:XGN) and SBC Medical Group (NASDAQ:SBC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

75.3% of Exagen shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 81.7% of SBC Medical Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Exagen presently has a consensus price target of $9.88, suggesting a potential upside of 139.10%. SBC Medical Group has a consensus price target of $8.00, suggesting a potential upside of 8.84%. Given Exagen's stronger consensus rating and higher possible upside, equities analysts plainly believe Exagen is more favorable than SBC Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
SBC Medical Group	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Exagen has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

SBC Medical Group has a net margin of 27.99% compared to Exagen's net margin of -25.14%. SBC Medical Group's return on equity of 18.47% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-25.14%	-125.60%	-33.46%
SBC Medical Group	27.99%	18.47%	13.10%

In the previous week, Exagen had 20 more articles in the media than SBC Medical Group. MarketBeat recorded 38 mentions for Exagen and 18 mentions for SBC Medical Group. SBC Medical Group's average media sentiment score of 0.46 beat Exagen's score of 0.30 indicating that SBC Medical Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	10 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral
SBC Medical Group	4 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.58	-$19.95M	-$0.75	N/A
SBC Medical Group	$173.61M	4.35	$50.99M	$0.47	15.64

Summary

SBC Medical Group beats Exagen on 10 of the 17 factors compared between the two stocks.

How does Exagen compare to Strata Critical Medical?

Strata Critical Medical (NASDAQ:SRTA) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Strata Critical Medical presently has a consensus target price of $8.00, suggesting a potential upside of 45.19%. Exagen has a consensus target price of $9.88, suggesting a potential upside of 139.10%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Strata Critical Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Strata Critical Medical	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Strata Critical Medical has a net margin of -8.84% compared to Exagen's net margin of -25.14%. Strata Critical Medical's return on equity of -2.71% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Strata Critical Medical	-8.84%	-2.71%	-2.31%
Exagen	-25.14%	-125.60%	-33.46%

Strata Critical Medical has a beta of 2.56, meaning that its stock price is 156% more volatile than the broader market. Comparatively, Exagen has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market.

In the previous week, Exagen had 33 more articles in the media than Strata Critical Medical. MarketBeat recorded 38 mentions for Exagen and 5 mentions for Strata Critical Medical. Strata Critical Medical's average media sentiment score of 0.55 beat Exagen's score of 0.30 indicating that Strata Critical Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Strata Critical Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Exagen	10 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral

47.4% of Strata Critical Medical shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 15.5% of Strata Critical Medical shares are held by insiders. Comparatively, 10.4% of Exagen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Strata Critical Medical has higher revenue and earnings than Exagen. Strata Critical Medical is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Strata Critical Medical	$197.14M	2.47	$41.35M	-$0.03	N/A
Exagen	$66.57M	1.58	-$19.95M	-$0.75	N/A

Summary

Strata Critical Medical beats Exagen on 10 of the 16 factors compared between the two stocks.

How does Exagen compare to Viemed Healthcare?

Exagen (NASDAQ:XGN) and Viemed Healthcare (NASDAQ:VMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Exagen has a beta of 2.25, suggesting that its stock price is 125% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Exagen currently has a consensus target price of $9.88, suggesting a potential upside of 139.10%. Viemed Healthcare has a consensus target price of $12.00, suggesting a potential upside of 30.86%. Given Exagen's stronger consensus rating and higher probable upside, research analysts plainly believe Exagen is more favorable than Viemed Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Viemed Healthcare	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20

Viemed Healthcare has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.58	-$19.95M	-$0.75	N/A
Viemed Healthcare	$270.28M	1.29	$14.93M	$0.38	24.13

75.3% of Exagen shares are owned by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are owned by institutional investors. 10.4% of Exagen shares are owned by company insiders. Comparatively, 20.6% of Viemed Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Viemed Healthcare has a net margin of 5.03% compared to Exagen's net margin of -25.14%. Viemed Healthcare's return on equity of 10.64% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-25.14%	-125.60%	-33.46%
Viemed Healthcare	5.03%	10.64%	7.73%

In the previous week, Exagen had 31 more articles in the media than Viemed Healthcare. MarketBeat recorded 38 mentions for Exagen and 7 mentions for Viemed Healthcare. Viemed Healthcare's average media sentiment score of 0.39 beat Exagen's score of 0.30 indicating that Viemed Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	10 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral
Viemed Healthcare	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Viemed Healthcare beats Exagen on 9 of the 17 factors compared between the two stocks.

How does Exagen compare to Berto Acquisition?

Exagen (NASDAQ:XGN) and Berto Acquisition (NASDAQ:TACO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, Exagen had 33 more articles in the media than Berto Acquisition. MarketBeat recorded 38 mentions for Exagen and 5 mentions for Berto Acquisition. Berto Acquisition's average media sentiment score of 1.33 beat Exagen's score of 0.30 indicating that Berto Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	10 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral
Berto Acquisition	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exagen has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, Berto Acquisition has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market.

Berto Acquisition has lower revenue, but higher earnings than Exagen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.58	-$19.95M	-$0.75	N/A
Berto Acquisition	N/A	N/A	N/A	N/A	N/A

Exagen presently has a consensus price target of $9.88, suggesting a potential upside of 139.10%. Given Exagen's stronger consensus rating and higher possible upside, analysts plainly believe Exagen is more favorable than Berto Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Berto Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Berto Acquisition has a net margin of 0.00% compared to Exagen's net margin of -25.14%. Berto Acquisition's return on equity of 0.00% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-25.14%	-125.60%	-33.46%
Berto Acquisition	N/A	N/A	N/A

75.3% of Exagen shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Comparatively, 13.2% of Berto Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Exagen beats Berto Acquisition on 8 of the 13 factors compared between the two stocks.

How does Exagen compare to InfuSystem?

InfuSystem (NYSE:INFU) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

InfuSystem has a net margin of 1.12% compared to Exagen's net margin of -25.14%. InfuSystem's return on equity of 2.78% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Exagen	-25.14%	-125.60%	-33.46%

In the previous week, Exagen had 34 more articles in the media than InfuSystem. MarketBeat recorded 38 mentions for Exagen and 4 mentions for InfuSystem. Exagen's average media sentiment score of 0.30 beat InfuSystem's score of 0.24 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InfuSystem	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exagen	10 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral

InfuSystem has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$144.44M	2.06	$870K	$0.45	32.71
Exagen	$66.57M	1.58	-$19.95M	-$0.75	N/A

InfuSystem has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, Exagen has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market.

71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by insiders. Comparatively, 10.4% of Exagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

InfuSystem presently has a consensus target price of $17.50, indicating a potential upside of 18.89%. Exagen has a consensus target price of $9.88, indicating a potential upside of 139.10%. Given Exagen's higher probable upside, analysts plainly believe Exagen is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

InfuSystem beats Exagen on 10 of the 17 factors compared between the two stocks.

Get Exagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XGN vs. The Competition

Export

Metric	Exagen	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$112.51M	$10.82B	$7.84B	$12.19B
Dividend Yield	N/A	2.54%	2.46%	4.53%
P/E Ratio	-5.51	36.37	34.71	28.44
Price / Sales	1.58	2.15	8.66	5.84
Price / Cash	N/A	23.34	21.93	22.49
Price / Book	7.65	3.71	4.35	3.76
Net Income	-$19.95M	$335.01M	$3.51B	$390.55M
7 Day Performance	-28.92%	-1.06%	-1.49%	-0.33%
1 Month Performance	-50.95%	-0.57%	-2.55%	-4.82%
1 Year Performance	-54.16%	21.17%	0.92%	-5.83%

Exagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XGN Exagen	4.1037 of 5 stars	$4.13 -6.3%	$9.88 +139.1%	-55.8%	$112.51M	$66.57M	N/A	220	Trending News Earnings Report Analyst Forecast Insider Trade High Trading Volume
SBC SBC Medical Group	2.8703 of 5 stars	$5.02 -0.1%	$8.00 +59.5%	+118.8%	$515.78M	$175.17M	10.67	863	Trending News Earnings Report Analyst Downgrade Gap Up
SRTA Strata Critical Medical	2.9116 of 5 stars	$5.56 +5.6%	$8.00 +44.0%	N/A	$493.03M	$280.76M	N/A	601
VMD Viemed Healthcare	4.1383 of 5 stars	$9.16 +1.7%	$14.00 +52.8%	+43.1%	$348.51M	$310.37M	24.08	1,382
TACO Berto Acquisition	1.4836 of 5 stars	$10.51 0.0%	N/A	+3.1%	$342.73M	N/A	N/A	7,892	Earnings Report Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XGN) was last updated on 11/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exagen (XGN) Competitors

XGN vs. SBC, SRTA, VMD, TACO, and INFU

How does Exagen compare to SBC Medical Group?

Summary

How does Exagen compare to Strata Critical Medical?

Summary

How does Exagen compare to Viemed Healthcare?

Summary

How does Exagen compare to Berto Acquisition?

Summary

How does Exagen compare to InfuSystem?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exagen (XGN) Competitors

XGN vs. SBC, SRTA, VMD, TACO, and INFU

How does Exagen compare to SBC Medical Group?

Do insiders & institutionals believe in XGN or SBC?

Do analysts prefer XGN or SBC?

Which has more volatility and risk, XGN or SBC?

Is XGN or SBC more profitable?

Does the media prefer XGN or SBC?

Which has preferable earnings & valuation, XGN or SBC?

Summary

How does Exagen compare to Strata Critical Medical?

Do analysts rate SRTA or XGN?

Is SRTA or XGN more profitable?

Which has more volatility & risk, SRTA or XGN?

Does the media favor SRTA or XGN?

Do insiders and institutionals hold more shares of SRTA or XGN?

Which has higher earnings & valuation, SRTA or XGN?

Summary

How does Exagen compare to Viemed Healthcare?

Which has more volatility & risk, XGN or VMD?

Do analysts recommend XGN or VMD?

Which has better valuation & earnings, XGN or VMD?

Do insiders & institutionals hold more shares of XGN or VMD?

Is XGN or VMD more profitable?

Does the media prefer XGN or VMD?

Summary

How does Exagen compare to Berto Acquisition?

Does the media prefer XGN or TACO?

Which has more volatility and risk, XGN or TACO?

Which has preferable earnings and valuation, XGN or TACO?

Do analysts prefer XGN or TACO?

Is XGN or TACO more profitable?

Do insiders and institutionals hold more shares of XGN or TACO?

Summary

How does Exagen compare to InfuSystem?

Is INFU or XGN more profitable?

Does the media refer more to INFU or XGN?

Which has better earnings & valuation, INFU or XGN?

Which has more risk & volatility, INFU or XGN?

Do institutionals & insiders believe in INFU or XGN?

Do analysts prefer INFU or XGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools